See more : Entero Healthcare Solutions Limited (ENTERO.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Olink Holding AB (publ) (OLK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Olink Holding AB (publ), a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Hybrid Financial Services Limited (HYBRIDFIN.BO) Income Statement Analysis – Financial Results
- Insmed Incorporated (0JAV.L) Income Statement Analysis – Financial Results
- Spice Private Equity AG (SPCE.SW) Income Statement Analysis – Financial Results
- SoftBank Group Corp. (0R15.L) Income Statement Analysis – Financial Results
- Lead Financial Services Limited (LEADFIN.BO) Income Statement Analysis – Financial Results
Olink Holding AB (publ) (OLK)
About Olink Holding AB (publ)
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 169.91M | 139.85M | 94.97M | 54.07M | 41.69M |
| Cost of Revenue | 71.04M | 45.35M | 36.76M | 17.46M | 13.02M |
| Gross Profit | 98.87M | 94.50M | 58.21M | 36.61M | 28.68M |
| Gross Profit Ratio | 58.19% | 67.57% | 61.29% | 67.71% | 68.78% |
| Research & Development | 30.57M | 26.35M | 22.14M | 9.63M | 4.85M |
| General & Administrative | 105.79M | 54.27M | 47.50M | 20.10M | 26.61M |
| Selling & Marketing | 12.24M | 44.67M | 33.67M | 12.72M | 8.25M |
| SG&A | 118.25M | 98.95M | 81.16M | 32.82M | 34.86M |
| Other Expenses | 0.00 | -191.00K | -443.00K | -475.00K | -363.00K |
| Operating Expenses | 148.81M | 125.10M | 102.86M | 41.98M | 39.34M |
| Cost & Expenses | 219.85M | 170.45M | 139.62M | 59.44M | 52.36M |
| Interest Income | 6.51M | 1.16M | 98.00K | 6.63M | 7.00K |
| Interest Expense | 858.00K | 531.00K | 2.05M | 6.63M | 6.60M |
| Depreciation & Amortization | 19.03M | 18.99M | 14.08M | 12.54M | 7.87M |
| EBITDA | -30.91M | -11.61M | -30.57M | 6.46M | -2.79M |
| EBITDA Ratio | -18.19% | -8.30% | -32.19% | 11.94% | -6.70% |
| Operating Income | -49.94M | -30.60M | -44.65M | -6.08M | -10.66M |
| Operating Income Ratio | -29.39% | -21.88% | -47.02% | -11.25% | -25.58% |
| Total Other Income/Expenses | 10.30M | 15.20M | -1.89M | -1.89M | -140.99K |
| Income Before Tax | -39.98M | -15.41M | -46.55M | -7.26M | -18.53M |
| Income Before Tax Ratio | -23.53% | -11.02% | -49.01% | -13.43% | -44.44% |
| Income Tax Expense | -8.32M | -2.56M | -8.21M | -479.00K | -652.00K |
| Net Income | -31.66M | -12.85M | -38.34M | -6.78M | -17.88M |
| Net Income Ratio | -18.63% | -9.19% | -40.37% | -12.54% | -42.88% |
| EPS | -0.26 | -0.11 | -0.39 | -0.03 | -0.07 |
| EPS Diluted | -0.26 | -0.11 | -0.39 | -0.03 | -0.07 |
| Weighted Avg Shares Out | 124.00M | 119.08M | 99.26M | 257.23M | 257.23M |
| Weighted Avg Shares Out (Dil) | 124.00M | 119.08M | 99.26M | 257.23M | 257.23M |
Olink to report second quarter 2023 financial results on August 9, 2023, and to participate in the Canaccord Genuity 43rd Annual Growth Conference
Announcing Olink® Explore HT – A New Era in Proteomics
Olink Holding AB (publ) (OLK) Q1 2023 Earnings Call Transcript
Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q1 Loss, Tops Revenue Estimates
Olink Holding AB (publ) Sponsored ADR (OLK) Moves to Strong Buy: Rationale Behind the Upgrade
Olink to report first quarter 2023 financial results on May 11, 2023
3 Medical Info Systems Stocks Countering Industry-wide Headwinds
Olink Holding AB (publ) (OLK) Q4 2022 Earnings Call Transcript
Olink Holding AB (publ) Sponsored ADR (OLK) Beats Q4 Earnings and Revenue Estimates
Olink: Proteomics Opportunity Exceeds Dilution Risk
Source: https://incomestatements.info
Category: Stock Reports